Abstract
Morbidity from degenerative aortic valve disease is increasing worldwide, concomitant with the ageing of the general population and the habitual consumption of diets high in calories and cholesterol. Immunohistologic studies have suggested that the molecular mechanism occurring in the degenerate aortic valve resembles that of atherosclerosis, prompting the testing of HMG CoA reductase inhibitors (statins) for the prevention of progression of native and bioprosthetic aortic valve degeneration. However, the effects of these therapies remain controversial. Although the molecular mechanisms underlying the onset of aortic valve degeneration are largely unknown, research in this area is advancing rapidly. The signaling components involved in embryonic valvulogenesis, such as Wnt, TGF-β1, BMP, and Notch, are also involved in the onset of aortic valve degeneration. Furthermore, investigations into extracellular matrix remodeling, angiogenesis, and osteogenesis in the aortic valve have been reported. Having noted avascularity of normal cardiac valves, we recently identified chondromodulin-I (chm-I) as a crucial anti-angiogenic factor. The expression of chm-I is restricted to cardiac valves from late embryogenesis to adulthood in the mouse, rat, and human. In human degenerate atherosclerotic valves, the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinases and angiogenesis is observed in the area of chm-I downregulation. Gene targeting of chm-I resulted in VEGF expression, angiogenesis, and calcification in the aortic valves of aged mice, and aortic stenosis is detected by echocardiography, indicating that chm-I is a crucial factor for maintaining normal cardiac valvular function by preventing angiogenesis. The present review focuses on the animal models of aortic valve degeneration and recent studies on the molecular mechanisms underlying the onset of degenerative aortic valve disease.
Similar content being viewed by others
References
Freeman RV, Otto CM (2005) Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111:3316–3326
Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS (2001) Bone formation and inflammation in cardiac valves. Circulation 103:1522–1528
Rajamannan NM, Gersh B, Bonow RO (2003) Calcific aortic stenosis: from bench to the bedside—emerging clinical and cellular concepts. Heart 89:801–805
Rajamannan NM, Otto CM (2004) Targeted therapy to prevent progression of calcific aortic stenosis. Circulation 110:1180–1182
Osman L, Yacoub MH, Latif N, Amrani M, Chester AH (2006) Role of human valve interstitial cells in valve calcification and their response to atorvastatin. Circulation 114:I547–552
Rajamannan NM, Bonow RO, Rahimtoola SH (2007) Calcific aortic stenosis: an update. Nat Clin Pract Cardiovasc Med 4:254–262
Skowasch D, Steinmetz M, Nickenig G, Bauriedel G (2006) Is the degeneration of aortic valve bioprostheses similar to that of native aortic valves? Insights into valvular pathology. Expert Rev Med Devices 3:453–462
Maganti K, Rajamannan N (2008) Slowing the progression of aortic stenosis. Curr Treat Options Cardiovasc Med 10:18–26
Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS (2001) Bone formation and inflammation in cardiac valves. Circulation 103:1522–1528
Kim KM (1976) Calcification of matrix vesicles in human aortic valve and aortic media. Fed Proc 35:156–162
Kim KM, Chang SH, Trump BF, Spurgeon H (1986) Calcification in aging canine aortic valve. Scan Electron Microsc 3:1151–1156
Ortolani F, Bonett A, Tubaro F, Petrelli L, Contin M, Nori SL, Spina M, Marchini M (2007) Ultrastructural characterization of calcification onset and progression in subdermally implanted aortic valves. Histochemical and spectrometric data. Histol Histopathol 22:261–272
Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T (2003) Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107:2181–2184
Lee YS, Chou YY (1998) Pathogenetic mechanism of senile calcific aortic stenosis: the role of apoptosis. Chin Med J (Engl) 111:934–939
Helske S, Kupari M, Lindstedt KA, Kovanen PT (2007) Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol 18:483–491
Aikawa E, Nahrendorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R (2007) Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation 115:377–386
O'Brien KD (2006) Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26:1721–1728
Hinton RB Jr., Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, Yutzey KE (2006) Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res 98:1431–1438
Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H (2004) Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110:1291–1295
Rosenhek R (2005) Statins for aortic stenosis. N Engl J Med 352:2441–2443
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352:2389–2397
Antonini-Canterin F, Zuppiroli A, Popescu BA, Granata G, Cervesato E, Piazza R, Pavan D, Nicolosi GL (2003) Effect of statins on the progression of bioprosthetic aortic valve degeneration. Am J Cardiol 92:1479–1482
Colli A, Gherli T, Mestres CA, Pomar JL (2007) Degeneration of native and tissue prosthetic valve in aortic position: do statins play an effective role in prevention? Int J Cardiol 116:144–152
Rajamannan NM, Sangiorgi G, Springett M, Arnold K, Mohacsi T, Spagnoli LG, Edwards WD, Tajik AJ, Schwartz RS (2001) Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis 10:371–374
Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC (2002) Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 105:2660–2665
Drolet MC, Arsenault M, Couet J (2003) Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 41:1211–1217
Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC (2005) Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112:I229–234
Guerraty M, Mohler ER 3rd (2007) Models of aortic valve calcification. J Investig Med 55:278–283
Tanaka K, Sata M, Fukuda D, Suematsu Y, Motomura N, Takamoto S, Hirata Y, Nagai R (2005) Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 46:134–141
Drolet MC, Roussel E, Deshaie Y, Couet J, Arsenault M (2006) A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol 47:850–855
Jian B, Jones PL, Li Q, Mohler ER 3rd, Schoen FJ, Levy RJ (2001) Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol 159:321–327
Mohler ER 3rd, Adam LP, McClelland P, Graham L, Hathaway DR (1997) Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 17:547–552
Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM (2002) Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol 161:2035–2046
Ghazvini-Boroujerdi M, Clark J, Narula N, Palmatory E, Connolly JM, DeFelice S, Xu J, Jian B, Hazelwood S, Levy RJ (2004) Transcription factor Egr-1 in calcific aortic valve disease. J Heart Valve Dis 13:894–903
Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, Hvass U, Couetil JP, Henin D, Michel JB, Vahanian A, Jacob MP (2005) Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 26:1333–1341
Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc A, Pinol R, Hagl S, Lang S, Brueckmann M, Borggrefe M (2005) Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 14:80–87
Hanada K, Vermeij M, Garinis GA, de Waard MC, Kunen MG, Myers L, Maas A, Duncker DJ, Meijers C, Dietz HC, Kanaar R, Essers J (2007) Perturbations of vascular homeostasis and aortic valve abnormalities in fibulin-4 deficient mice. Circ Res 100:738–746
Kyndt F, Gueffet JP, Probst V, Jaafar P, Legendre A, Le Bouffant F, Toquet C, Roy E, McGregor L, Lynch SA, Newbury-Ecob R, Tran V, Young I, Trochu JN, Le Marec H, Schott JJ (2007) Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation 115:40–49
Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM (2006) Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47:1707–1712
Johnson ML, Rajamannan N (2006) Diseases of Wnt signaling. Rev Endocr Metab Disord 7:41–49
Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA (2004) Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 95:253–260
Mohler ER 3rd, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH (1999) Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 8:254–260
Clark-Greuel JN, Connolly JM, Sorichillo E, Narula NR, Rapoport HS, Mohler ER 3rd, Gorman JH 3rd, Gorman RC, Levy RJ (2007) Transforming growth factor-beta1 mechanisms in aortic valve calcification: increased alkaline phosphatase and related events. Ann Thorac Surg 83:946–953
Kaden JJ, Bickelhaupt S, Grobholz R, Vahl CF, Hagl S, Brueckmann M, Haase KK, Dempfle CE, Borggrefe M (2004) Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 13:560–566
Choi M, Stottmann RW, Yang YP, Meyers EN, Klingensmith J (2007) The bone morphogenetic protein antagonist noggin regulates mammalian cardiac morphogenesis. Circ Res 100:220–228
Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MA Jr., Falb D, Huszar D (2000) A role for smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24:171–174
Timmerman LA, Grego-Bessa J, Raya A, Bertran E, Perez-Pomares JM, Diez J, Aranda S, Palomo S, McCormick F, Izpisua-Belmonte JC, de la Pompa JL (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev 18:99–115
Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D (2005) Mutations in NOTCH1 cause aortic valve disease. Nature 437:270–274
Garg V (2006) Molecular genetics of aortic valve disease. Curr Opin Cardiol 21:180–184
Mohamed SA, Aherrahrou Z, Liptau H, Erasmi AW, Hagemann C, Wrobel S, Borzym K, Schunkert H, Sievers HH, Erdmann J (2006) Novel missense mutations (p.T596M and p.P1797H) in NOTCH1 in patients with bicuspid aortic valve. Biochem Biophys Res Commun 345:1460–1465
Lange AW, Yutzey KE (2006) NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K. Dev Biol 292:407–417
Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M (2004) Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36:57–66
Kaden JJ, Dempfle CE, Kilic R, Sarikoc A, Hagl S, Lang S, Brueckmann M, Borggrefe M (2005) Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Exp Mol Pathol 78:36–40
Osman L, Chester AH, Sarathchandra P, Latif N, Meng W, Taylor PM, Yacoub MH (2007) A novel role of the sympatho-adrenergic system in regulating valve calcification. Circulation 116:I282–287
Golubnitschaja O, Yeghiazaryan K, Skowasch D, Schild H, Bauriedel G (2006) p21WAF1/CIP1 and 14-3-3 sigma gene expression in degenerated aortic valves: a link between cell cycle checkpoints and calcification. Amino Acids 31:309–316
Yeghiazaryan K, Skowasch D, Bauriedel G, Schild H, Golubnitschaja O (2007) Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement. Amino Acids 32:109–114
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38
Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75–81
Roth BL (2007) Drugs and valvular heart disease. N Engl J Med 356:6–9
Shukunami C, Oshima Y, Hiraki Y (2005) Chondromodulin-I and tenomodulin: a new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues. Biochem Biophys Res Commun 333:299–307
Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI, Sebo TJ, Rosengart TK, Edwards WD, McCarthy PM, Bonow RO, Spelsberg TC (2005) Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation 111:3296–3301
Chalajour F, Treede H, Gehling UM, Ebrahimnejad A, Boehm DH, Riemer RK, Ergun S, Reichenspurner H (2007) Identification and characterization of cells with high angiogenic potential and transitional phenotype in calcific aortic valve. Exp Cell Res 313:2326–2335
Chalajour F, Treede H, Ebrahimnejad A, Lauke H, Reichenspurner H, Ergun S (2004) Angiogenic activation of valvular endothelial cells in aortic valve stenosis. Exp Cell Res 298:455–464
Skowasch D, Schrempf S, Wernert N, Steinmetz M, Jabs A, Tuleta I, Welsch U, Preusse CJ, Likungu JA, Welz A, Lüderitz B, Bauriedel G (2005) Cells of primarily extra-valvular origin in degenerative aortic valves and bioprostheses. Eur Heart J 26:2576–2580
Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N, Shukunami C, Okada Y, Mukai M, Shin H, Yozu R, Sata M, Ogawa S, Hiraki Y, Fukuda K (2006) Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 12:1151–1159
Hiraki Y (1991) [Molecular cloning of a novel cartilage-specific functional matrix, chondromodulin-I, and its role in endochondral bone formation]. Seikagaku 63:1449–1454
Hiraki Y, Shukunami C (2005) Angiogenesis inhibitors localized in hypovascular mesenchymal tissues: chondromodulin-I and tenomodulin. Connect Tissue Res 46:3–11
Davis GE, Senger DR (2005) Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 97:1093–1107
Zijlstra A, Aimes RT, Zhu D, Regazzoni K, Kupriyanova T, Seandel M, Deryugina EI, Quigley JP (2004) Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). J Biol Chem 279:27633–27645
Lester W, Rosenthal A, Granton B, Gotlieb AI (1988) Porcine mitral valve interstitial cells in culture. Lab Invest 59:710–719
Oshima Y, Shukunami C, Honda J, Nishida K, Tashiro F, Miyazaki J, Hiraki Y, Tano Y (2003) Expression and localization of tenomodulin, a transmembrane type chondromodulin-I-related angiogenesis inhibitor, in mouse eyes. Invest Ophthalmol Vis Sci 44:1814–1823
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hakuno, D., Kimura, N., Yoshioka, M. et al. Molecular mechanisms underlying the onset of degenerative aortic valve disease. J Mol Med 87, 17–24 (2009). https://doi.org/10.1007/s00109-008-0400-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-008-0400-9